For patients with HIV without genotype information, a second-line switch to dolutegravir is noninferior to a regimen containing a ritonavir-boosted protease inhibitor (PI), according to a study published in the June 22 issue ...
Jun 23, 2023
0
2
(HealthDay)—Monthly long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV) are noninferior to daily regimens for patients with HIV-1, according to two studies presented at the Conference on Retroviruses and Opportunistic ...
Mar 12, 2019
0
2
The latest World Health Organization (WHO) recommendations published in July 2018 advocate first-line treatment of HIV infection using dolutegravir (DTG) as an alternative to treatment with efavirenz at 400 mg (EFV400). Until ...
Nov 1, 2018
0
0
An observational study found that gender/sex disparities in the use of dolutegravir-containing antiretroviral therapy (ART) persist despite World Health Organization (WHO) endorsement for its use among women with HIV of reproductive ...
Nov 30, 2021
0
3
Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. In an early benefit ...
May 21, 2014
0
0
Children born to women on HIV therapy containing the drug dolutegravir since conception have a slightly higher risk of neural tube defects, compared to children born to women on regimens of other antiretroviral drugs. The ...
Jul 22, 2019
0
1
